SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices climb amid fears of supply disruptions from Middle East shipping and energy-infrastructure attacks, with traders also watching Ukrainian strikes on Russian oil assets. Bulls cite the supply risks, while bears argue the rally is stretched and could reverse if diplomacy or eased Russian sanctions restores supply; higher oil is also fueling inflation concerns and pressure on broader markets.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO slide to fresh lows is drawing attention, with traders citing share-unlock overhang and insider selling, alongside a TD Cowen price-target cut and concerns about OpenAI customer concentration and competition from Nvidia. The community is split between buyers calling the stock oversold and bears expecting further pressure until lockup expirations pass and the company demonstrates growth and scaling.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff is centered on concerns about its debt-heavy expansion and costly financing, with HSBCs bearish assessment adding to worries that AI demand may not translate into adequate returns. Traders are split between viewing the backlog and ongoing AI demand as a buying opportunity and fearing that credit costs and refinancing needs could constrain growth; a Goldman upgrade has not settled the debate.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale shares are under pressure after UBS downgraded the stock to Sell, citing long commercialization timelines and a lack of firm customer commitments, amid questions about delays to the proposed TVA deployment. Traders are split between viewing the selloff as an overreaction to the rating and seeing it as a warning about execution risk and the companys ability to turn its reactor technology into binding projects.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicors Q3 results are driving attention: traders cite strong revenue growth and margins but debate the GAAP EPS miss and the absence of forward guidance, with many waiting for the earnings-call outlook to assess the report and valuation.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led rebound after the AI-linked selloff has QQQ traders debating whether the move is a lasting recovery or a brief relief rally, with upcoming megacap earnings seen as a test. Concerns about AI infrastructure spending and credit risks, alongside surging oil and inflation worries, are keeping sentiment volatile.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStops reminder that its warrants will expire unexercised if holders miss the deadline has become the main focus, with the share price below the exercise threshold. Traders disagree over whether the warrants will lapse and remove a potential dilution overhang or whether Ryan Cohen will take action to make them valuable; some warrant holders express frustration while bulls point to his recent share purchases.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a sharp AI-infrastructure selloff, as traders debate neocloud funding risks and Gartners warning that many providers may face consolidation. The community is split between viewing the recent bounce as an oversold relief move and expecting further weakness; bulls argue Nebius may be better positioned than debt-heavy peers and could benefit if demand shifts.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs Q3 earnings beat and stronger cash-flow outlook, alongside a new share-repurchase authorization, are driving discussion. Traders are weighing those positives against the stocks decline, pointing to a narrowed but unchanged-midpoint profit outlook and softer U.S. sales as reasons the beat did not spark a stronger reaction.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is drawing attention after reporting a strong third-quarter earnings beat and raising its full-year sales, earnings, and cash-flow outlook, with strength across its aerospace and defense businesses. Traders are broadly positive, though some question how much of the guidance increase reflects IEEPA cost recovery versus underlying growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viatris Receives U.S. FDA Approval for RYZUMVI for the Treatment of Presbyopia

Viatris Receives U.S. FDA Approval for RYZUMVI for the Treatment of Presbyopia Viatris Receives U.S. FDA Approval for RYZUMVI for the Treatment of PresbyopiaPR NewswirePITTSBURGH, Oct. 16, 2026 PITTSBURGH, Oct. 16, 2026 /PRNewswire/ -- Viatris Inc.(Nasdaq: VTRS), a global healthcare company, today...

Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment

Equity

The approval expands the therapy's use and triggers a milestone payment from commercial partner Viatris.

Dow Takes Over #374 Spot From Viatris

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Dow Inc (Symbol: DOW) has taken over the #374 spot from Viatris Inc (Symbol: VTRS), according to The Online Investor.

 Market capitalization is an important data point...

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira...

Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus

Wall Street is abuzz with deal chatter as major healthcare, beverage, and oil companies eye significant deals in the coming weeks.

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist 

JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights

Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents. 


Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy

Major M&A deals this week include Viatris buys Pacira BioSciences, TowneBank acquires blueharbor, Energy Transfer buys Vacquero Midstream.read more...

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.

HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?

Pacira BioSciences secured a $1.65 billion buyout deal with Viatris, while Haemonetics expanded its CSL Plasma partnership, prompting BTIG to raise its price target.

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan, and Hong Kong. The JANZ segment covers operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses operations in developing markets and emerging economies including in Asia, the Middle East, South and Central America, Africa, and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Viatris Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Ryzumvi contains phentolamine ophthalmic solution 0.75%, which reduces pupil size to improve near vision without affecting longer-distance vision.</li><li>The approval was supported by two Phase 3 trials.</li><li>Opus is studying Ryzumvi for vision problems in dim lighting after laser eye surgery.</li></ul>Opus Genetics (IRD) was in the spotlight on Friday, after the U.S. Food and Drug Administration approved its eye drop for treating presbyopia, an age-related condition that makes it difficult to focus on nearby objects.The approval expands the use of an already commercialized therapy and triggers a milestone payment from commercial partner Viatris (VTRS).At the time of writing, <a class="mention" data-mention="$IRD" data-symbol-id="IRD" href="https://stocktwits.com/symbol/IRD" target="_blank">IRD shares</a> were trading 3.4% lower, while <a href="https://stocktwits.com/symbol/VTRS">VTRS stock</a> gained about 1%.<h2 class="st-heading-2">Approval Based On Two Phase 3 Trials</h2>Opus’ Ryzumvi contains phentolamine ophthalmic solution 0.75%, which reduces pupil size to improve near vision without affecting longer-distance vision. The approval was supported by two Phase 3 trials, VEGA-2 and VEGA-3, which met their primary and key secondary goals without serious treatment-related side effects.Notably, 27.2% of patients receiving the eye drop saw an improvement of at least 15 letters (three lines) on an eye chart, compared with 11.5% receiving a placebo.The drug previously received <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0001140361-25-011410/ef20039022_10k.htm">FDA approval</a> in September 2023 to reverse pupil dilation caused by medications used during eye examinations. Viatris launched it commercially in April 2024.The companies’ licensing <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1228627/000114036126009247/ef20060643_10k.htm">agreement</a> dates back to November 2022, when Ocuphire Pharma, which acquired Opus in October 2024, granted Viatris the rights to commercialize the treatment.The agreement included $35 million upfront, up to $130 million in milestone payments, and royalties.<h2 class="st-heading-2">IRD Finances To Support Operations Into 2029</h2>Opus is developing gene therapies for inherited retinal diseases, including OPGx-BEST1 for Best disease and OPGx-LCA5 for severe inherited vision loss. The company is also studying Ryzumvi for vision problems in dim lighting following laser eye surgery.Opus reported $88.8 million in cash and cash equivalents as of June 30, and has a financing option of up to $120 million under an agreement with Oberland Capital. The company expects its cash position to support operations into 2029.<h2 class="st-heading-2">IRD, VTRS See Strong Gains In 2026</h2>Retail sentiment surrounding both IRD on Stocktwits flipped to ‘extremely bullish’ from ‘neutral’ over the past 24 hours, amid ‘high’ message volumes. Meanwhile, sentiment for VTRS remained ‘neutral’.IRD shares have seen strong buying interest so far this year, surging 84%. Meanwhile, VTRS stock has gained about 48%.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/mi-medx-sanara-merger-faces-fresh-regulatory-obstacle-smti-stock-falls-below-this-key-support-level-for-the-first-time-in-4-months/cZxKJ0GRBsM">MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Opus Genetics Inc.

SPDR S&P Biotech ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$18.26
Prev Close	$18.66
Open	$18.63
Dividend Yield	3.86%
50-Day Moving Average	$17.01
Beta	0.74
Avg. Volume	8.88M
PE Ratio	-51.12

52-Week High	$18.75
52-Week Low	$9.92
Market Capitalization	$21.43B
EPS (Annual)	-$3.00
Price to Book	1.48
Revenue Per Employee	$476,440.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

VTRS Fundamentals